Downloading...
Download

Mrnasignal

Moderna Faces Another Quarterly Loss, Yet Shares Show ResilienceModerna Inc. (NASDAQ: NASDAQ:MRNA ) has once again reported a quarterly loss, reflecting the continued decline in COVID-19 vaccine sales and an unexpected charge related to a canceled manufacturing contract. Despite this, shares of the biotech giant saw a 3.35% uptick, signaling a mixed sentiment among investors. Weighing the Challenges and Opportunities On Friday, Moderna disclosed a Q4 2024 revenue of $966 million, marking a sharp 65% year-over-year decline. The loss per share stood at $2.91, exceeding the analyst projection of $2.73 per share. More concerning for investors was the company’s forecast for 2025 sales, estimated between $1.5 billion and $2.5 billion—significantly below the $3.26 billion consensus estimate. CEO Stéphane Bancel reaffirmed Moderna’s focus on cutting costs and streamlining its research and development (R&D) efforts. The company plans to reduce R&D expenses by up to $1.1 billion by 2027, primarily by halting early-stage projects and prioritizing late-stage drug approvals. Moderna has already trimmed $1 billion in costs, positioning itself for leaner operations in the coming years. Technical Analysis: Key Levels to Watch From a technical perspective, NASDAQ:MRNA shares closed Friday’s session down 0.38%, showing hesitation despite the broader market’s strength. The stock is currently hovering near a critical support zone—the one-month low. Should this level fail to hold, a further decline towards the $25 region could be the next stop. On the upside, a breakout above the 38.2% Fibonacci retracement level could alter the trajectory for Moderna’s stock, potentially signaling a bullish reversal. However, with the Relative Strength Index (RSI) at 41.46, the stock remains in weak momentum territory, suggesting that bullish conviction is still lacking. Outlook: Can Moderna Reignite Investor Confidence? Moderna’s near-term outlook remains uncertain, as the company grapples with declining COVID vaccine sales, weaker-than-expected 2025 revenue projections, and an ongoing shift in its R&D strategy. However, its pipeline of combination vaccines and upcoming approvals may offer a longer-term upside if execution is successful. Technically, NASDAQ:MRNA needs to hold its key support zone and break above the 38.2% Fibonacci retracement to shift market sentiment positively. Until then, investors should watch for further signals of strength, particularly in trading volume and RSI movement, before confirming a potential bullish turnaround. In the coming months, all eyes will be on Moderna’s next earnings report and the market’s reaction to its cost-cutting measures and pipeline advancements. The stock’s ability to sustain recent gains—or break lower—will depend on whether the company can deliver on its strategic shifts and stabilize its revenue trajectory.
NASDAQ:MRNALong
by DEXWireNews
Halftime Update: MRNA - Moderna AnalysisMRNA is currently retesting a pivotal level of resistance that we believe could provide a greater push back to those higher $58.55 Price Levels as long as it can keep this momentum that it has, seeing a very large volume spike in this morning. If not, we would expect some consolidation back to $45.42 levels before pushing higher. Stock jumped this morning after reporting a potential vaccine to combat the recent H5N1 Bird Flu. This comes after the first human death due to the Bird Flu in Louisiana, although the patient did have pre-existing medical conditions that contributed to the death, not to stir any feathers. Don't really have a price projection or entry specifically for this as we're watching. This could pull back to those EMAs before gaining True Momentum Northward. Connect with us by visiting the website below in our signature to get even more at @MyMIWallet #MyMIWallet
NASDAQ:MRNALong
by MyMIWallet
MRNA is going to dump now / where to buyMRNA is not looking too good. What we can see is a weekly bearish engulfing candle after clear rejection from the upsloping resistance line. Rejection was nasty therefore we're seeing instant follow through. You can short it now with a final target at the support which is the entry for longs too. At the support, flip bullish and take a long position. The target is at the key resistance shown on the chart. If you short now, pleace a stop loss at 219 - 220 $ Good luck
NASDAQ:MRNAShort
by vf_investment
8
MRNA Overbought Condition with Daily Bearish Wolfe wave SetupThere is a daily wolfe wave setup that triggered on December 15. Today at the open, MRNA opened inside day and traded +4% within 30 mins of the trading day. The projected target is calculated by extending a linear line between pivot 1 and 4 and projecting the line; however, the linear lines do not converge. The projected target is approx 167 which is represented as the red perforated line. The target price coincides with the 50 day ma as shown in the chart. Using the customizable gap finder indicator there is a larget gap left open from the Dec 12 kicker. It is likely to fill the gap within 2 weeks time.
NASDAQ:MRNAShort
by TOSOPTION
Moderna at key resistance? Moderna Short Term We look to Sell at 183.71 (stop at 203.39) Preferred trade is to sell into rallies. Previous resistance located at 190.00. Trading within a Bearish Channel formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 121.74 and 94.19 Resistance: 190.00 / 220.00 / 495.00 Support: 156.00 / 120.00 / 100.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Shooting Star on Moderna? Moderna Short Term We look to Sell at 146.42 (stop at 154.23) Preferred trade is to sell into rallies. Price action has posted a bearish Shooting Star and is negative for short-term sentiment. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 122.21 and 94.19 Resistance: 150.00 / 171.76 / 187.50 Support: 120.00 / 100.00 / 66.41 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Feeling sick? (Moderna)Moderna Short Term We look to Sell at 133.52 (stop at 141.88) Preferred trade is to sell into rallies. Prices expected to stall near trend line resistance. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. The bias is still for lower levels and we look for any gains to be limited. Our profit targets will be 105.41 and 94.19 Resistance: 150.00 / 171.76 / 187.50 Support: 116.00 / 100.00 / 66.41 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis , like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis , as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
Moderna: Sell the Break Setup Moderna - Short Term - We look to Sell a break of 137.05 (stop at 147.24) A move through bespoke support at 140.00 and we look for extended losses. Closed below the 20-day EMA. The primary trend remains bearish. Our overall sentiment remains bearish looking for lower levels. We look to set shorts in the early trade. Our profit targets will be 108.99 and 103.50 Resistance: 150.00 / 170.00 / 200.00 Support: 140.00 / 120.00 / 100.00 Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features. Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
NASDAQ:MRNAShort
by Saxo
2
MRNA Daily TimeframeSNIPER STRATEGY (new version) It works ALMOST ON ANY CHART. It produces Weak, Medium and Strong signals based on consisting elements. NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear. TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS. ENTRY PRICE BLACK COLOR TARGETS GREEN COLOR STOP LOSS RED COLOR DO NOT USE THIS STROTEGY FOR LEVERAGED TRADING. It will not give you the whole wave like any other strategy out there but it will give you a huge part of the wave. The BEST TIMEFRAMES for this strategy are Daily, Weekly and Monthly however it can work on any timeframe. Consider those points and you will have a huge advantage in the market. There is a lot more about this strategy. It can predict possible target and also give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts. START BELIEVING AND GOOD LUCK HADIMOZAYAN
NASDAQ:MRNAShort
by hadimozayan
MODERNA Daily TimeframeSNIPER STRATEGY This magical strategy works like a clock on almost any charts Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading. It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave. The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes. Start believing in this strategy because it will reward believers with huge profit. There is a lot more about this strategy. It can predict and also it can give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
NASDAQ:MRNAShort
by hadimozayan
4
MRNA Moderna vs PFE Pfizer | Head and Shoulders patternIf you haven`t longed Moderna with me from here: Then you should realize that the head an shoulders pattern on descending volume of a company that worth 53.402B, but has 747Mil negative earnings for 2020, may lead to $100 per share. On the other hand, undervalued, it`s Pfizer , which has the same amazing results with the vaccine, lots of medicine in the portfolio, a market cap almost 4 times higher, 198.973B and positive earnings of 9.62Bil. The pay also great dividends, btw, 4.38% DIV YIELD on a decent 20.82 P/E ratio . If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:MRNAShort
by TopgOptions
8
Moderna (MRNA) Bounce ComingApproaching 200 MA Gap filled Oversold Revenue will sky rocket with all of the vaccine orders MACD is improving Yes its pharma, yes it looks like a dumpster fire and we cant trust them BUT I can't help it. I see a bounce form $95-105 range to $135-155 range if not back to ATH after all the vaccine orders materialize in actual revenues. We might still dip more but keep a close eye on it. We dont even have to worry about technicals, Fauci and the boys will pump this up.
NASDAQ:MRNALong
by bossmodetrader
4
MRNA Moderna vaccine 94.5% effective in Phase 3 trial!This was my previews post about Moderna: The indicators are still bullish. The price of the stock grew 5X since the beginning of the year. 11/16/2020 Oppenheimer Boost Price Target ➝ $157.00 11/16/2020 Piper Sandler Boost Price Target ➝ $166.00 The traditional method of creating vaccines – introducing a weakened or dead virus, or a piece of one, to stimulate the body's immune system – takes over a decade on average, according to a 2013 study. One pandemic flu vaccine took over eight years while a hepatitis B vaccine was nearly 18 years in the making. Moderna's vaccine went from gene sequencing to the first human injection in 63 days. Moderna and BioNTech, for example, are also applying mRNA technology to experimental cancer medicines. BioNTech's vaccine, for example, must be transported at minus 70 degrees Celsius, though Moderna said on Monday it can ship its candidate in normal refrigerators. (Reuters) If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
NASDAQ:MRNALong
by TopgOptions
MRNA HOLD BULLISHI am not swinging this one, even though it is tempting. I recently sold NVAX at 15% profit, and due to strong correlation with MRNA I was considering selling my MRNA as well, in which case I would have made 14% right now. However, I decided to hold because of 2 reasons : 1) AstraZeneca just took a major hit (if you don't know about it, catch up on the news). This takes out a bit of competition and investor fund distribution might come this way 2) MRNA shows a strong uptrend with good momentum, and that is mainly why I will HOLD it for longer term. Hit like if you found this helpful and interesting. Thanks, E
NASDAQ:MRNA
by BlockTechEv
9
MRNA - THE CEO THAT SOLD - SHARE YOUR FEEDBACKPLEASE READ THE ENTIRE POST, IT MIGHT JUST SAVE YOU A SOUR INVESTMENT I have been following MRNA for about a month now, and something interesting has happened that not many people know about. On 4 September, news came out that the CMO, the President AND the CEO have sold large if not all of their holdings.* Now the company says that this is no reason to panic. (sounds like what we were told about corona in December...) On the trading platform I use, I have also gotten a notification about insiders selling. This is a built in strategy used along with others to determine the market consensus of the stock (buy, strong buy, hold etc) We can all probably agree that when head management sell most of their holdings, and not 1 person but 3 senior members, it is generally not a good sign. Now here is where I'd like your feedback - The large selling off their stocks hasn't been reflecting in the market. In fact, MRNA has been on one long bull run with minor short term bearish chart patterns. Why would it be that the sell off doesn't reflect in the market? I personally sold my stock immediately after I saw a report on this from Gurufinder, later confirmed by more mainstream news and other platforms. My opinion is that The company has to portray that they believe their stocks are going all the way up which in this case, selling off massive holdings at the peak tells me that they are taking their profit. Compare this to PFE (Pfizer), whos director INCREASED his holdings. Now that speaks of confidence in the company, right? * INFO FROM MY TRADING PLATFORM CEO, SOLD $1,293,810, DATE 18.09.20 PRESIDENT, SOLD $1,228,468, DATE 15.09.20 CMO, SOLD $1,255,321, DATE 15.09.20 Please share your constructive and respectful feedback, and thank you ! Hit like if you found this interesting, Ev
NASDAQ:MRNA
by BlockTechEv
7
Analysis on Moderna (Vaccine Company)Moderna (MRNA) is developing a COVID-19 vaccine candidate that is widely considered one of the frontrunners to bring a vaccine to market; it was the first company to share data about how its experimental vaccine performed in a Phase 1 clinical trial. It has so far soared more than 350% since the start of the year. The main reason is that there has been tremendous widespread investor interest on their vaccination project, and the obvious unmet need/opportunity for a COVID-19 vaccine. However, J.P. Morgan just recently downgraded the rating on Moderna (MRNA) and signal that its currently overvalued. I feel that if the price dips or there's any pullback, would be a good opportunity to enter for a short hold and probably selling it upon the next peak which I believe would be around their Phase 3 trials. Because long term hold on Moderna might be risky since more often than not, vaccines usually takes a long time before it actually gets released and for the company to be actually profitable.
NASDAQ:MRNALong
by Trader_hao
1